Article Text
Abstract
Introduction To assess the utility of circulating tumor DNA (ctDNA) in monitoring the response to pegylated liposomal doxorubicin (PLD) in platinum-resistant ovarian cancer (PROC), and to evaluate the consistency of circulating tumor DNA with imaging and CA125.
Methods This is a single-arm, single-center prospective observational study (NCT05976932). PROC patients with histopathological diagnosis of high-grade serous cancer and TP53 gene mutations were enrolled. After enrollment, patients will receive PLD alone (40 mg/m2, intravenously, every 4 weeks) and follow-up strategy. Peripheral blood ctDNA will be tested for TP53 genetic variation based on next-generation sequencing (NGS). Imaging evaluation was assessed according Response Evaluation Criteria in Solid Tumors (RECIST), version 1.1.
Results Since June 2023, nine patients have completed at least two cycles of treatment and the mean duration of treatment was 3.1 cycles. All patients had elevated CA125 levels, while four patients experienced progressive disease (PD) at first imaging evaluation. ctDNA was performed in the first four enrolled patients, and patient 4 had negative ctDNA level. ctDNA levels of the rest three patients was consistent with imaging interpretation. ctDNA monitoring panels for other enrolled patients is still under construction.
Conclusion/Implications Elevated CA125 levels was common at early treatment cycles of PLD. ctDNA levels showed potential in monitoring platinum-resistant ovarian cancer.